eipt date: 03/04/2003

I hereby certify that this correspondence is being deposited with the United

States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents

Washington, D.C. 20231

tehnay 20

TOWNSEND and TOWNSEND and CREW LLP

09432503 - GAU: 1635

PATENT

Attorney Docket-No.: 015389-002611US

Client Reference No.: 018/063C

RECEIVED

MAR 0 7 2003

TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Geron Corporation

Application No.: 09/432,503

Filed: November 2, 1999

For:

HUMAN TELOMERASE

CATALYTIC SUBUNIT

Examiner: Peter P. Tung

Art Unit: 1652

SUPPLEMENTAL INFORMATION **DISCLOSURE STATEMENT UNDER 37**

CFR §1.97 and §1.98

Assistant Commissioner for Patents Washington, D.C. 20231

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. With the exception of references AV, AW and AX, copies of which are enclosed, copies of the references can be found in U.S. Patent Application 08/912,951 filed August 14, 1997 (now U.S. Patent 6,475,789, issued November 5, 2002).

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

Receipt date: 03/04/2003

Geron Corporation

Application No.: 09/432,503

Page 2

09432503 - GAU: 1635

<u>PATENT</u>

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

This IDS is being filed before the mailing date of the final Office Action or Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

Scott L. Ausenhus Reg. No. 42,271

TOWNSEND and TOWNSEND and CREW LLP Two Embarcadero Center, 8th Floor San Francisco, California 94111-3834

Tel: 303-571-4000 Fax: 303-571-4321

SLA:mcl

DE 7096175 v1

Substitut BADE 1449A/PTO

PTO/SB/08A (10-01) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Complete if Known

work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control <u>num</u>ber

Examiner Name

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 09/432,503 **Filing Date** November 2, 1999 First Named Inventor Cech, Thomas R., et. al. Art Unit 1652

Peter P. Tung

(use as many sheets as necessary)

12 015389-002611U Sheet 3 Attorney Docket Number

	14/2	$\boldsymbol{\omega}$	_	
S	TEOL	77	U	1
	-CH CE	N	77	_

			U.S. PATENT D	OCUMENTS	- NIER 160
		Document Number			
Examiner	Cite No. ¹	Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	08/751,189	11-15-96	Harrington, et al.	
	AB	60/038,750	02-20-1997	Counter, et al.	
	AC	3,817,837	06-18-1974	Tanenholtz et al.	
	AD	3,850,752	11-26-1974	Schuurs et al.	
	AE	3,939,350	02-17-1076	Kronick et al.	
	AF	3,996,345	12-01-1976	Ullman et al.	
	AG	4,275,149	06-23-1081	Litman et al.	
	AH	4,277,437	07-07-1981	Maggio	
	Al	4,366,241	12-28-1982	Tom et al.	
	AJ	4,683,195	07-28-1987	Mullis et al.	
	AK	4,683,202	07-28-1987	Mullis	
	AL	4,816,567	03-28-1989	Cabilly et al.	
	AM	4,965,188	10-23-1990	Mullis et al.	
	AN	5,489,508	02-06-1996	West et al.	
	AO	5,583,016	12-10-1996	Villeponteau et al.	
	AP	5,747,317	05-05-1998	Cao	
	AQ	5,770,422	06-23-1998	Collins	•
	AR	6,093,809	07-25-2000	Cech, et al.	
	AS	6,258,535 - B1	07-10-2001	Villeponteau et al.	2,30
	AT	6,261,556 - B1	07-17-2001	Weinrich et al.	
	AU	6,261,836 - B1	07-17-2001	Cech et al.	
	AV	6,093,809	07-25-2000	Cech et al.	
	AW	6,166,178	12/26-2000	Cech et al.	
	AX	6,475,789 B1	11-05-2002	Cech et al.	

		Eor	eign.Patent Document		Name of Patentee or	Pages, Columns, Lines,-	
	Cite No. ¹	Country Code ³	Number ⁴ Kind Code ^s (<i>if known</i>)	Publication Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T ⁶
	AY	JP	09154575-A		06-17-97		
	AZ	PCT	WO 84/03564	-	09-13-84		
	BA	PCT	WO 95/13382		05-18-95		
	BB	PCT	WO 96/01835		01-25-96		
	ВС	PCT	WO 96/12811		05-02-96		
	BD	PCT	WO 96/19580		06-27-96		
	BE	PCT	WO 96/40868		12-19-96		
Examiner Signature		PCT	WO 96/40868	Date Considere			

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 2023 1. DO NOT SEND EEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Assistant Commissioner for OUGH. /JEA/Patents, WANTINGTON FOR 2023 HENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /JEA/

DE 7096175 v1

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

PTO/SB/08A (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

1652

COMME. control number.

MAR 0-7

15. CH CENTER 1600 2900 work Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control n Substitute for form 1449A/PTO Complete if Known 09/432,503 **Application Number** INFORMATION DISCLOSURE Filing Date November 2, 1999 STATEMENT BY APPLICANT **First Named Inventor** Cech, Thomas R., et. al.

Art Unit

(use as many sheets as necessary) **Examiner Name** Peter P. Tung Sheet 4 12 Attorney Docket Number 015389-002611US

			FOREIGN PA	TENT DOCUME	NTS		
Examiner Cite No.1		For	eign Patent Document		Alama of Datastas as	Pages, Columns, Lines,	
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	Τ'
	BF	PCT	WO 98/01542		01-15-98		
-	BG	PCT	WO 98/01543		01-15-98		
-	BH	PCT	WO 98/07838		03-05-98		
	ВІ	PCT	WO 98/08938		02-26-98		
	BJ	PCT	WO 98/21343		05-22-98	-	
· -	ВК	PCT	WO 98/37181		08-27-98		
	BL	PCT	WO 98/45450		10-15-98		
	ВМ	PCT	WO98/59040		12/30/98		
	BN	PCT	WO99/01560		01/14/99		

Examiner Signature	Date Considered	_	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 2023 Line NOT SEND EFES OR COMPLETED ECRMS TO THIS ADDRESS, SEND TO Assistant Commissioner (of the Patents, WANTINGTON DETAILS OF THE COMPLETE CONSIDERED EXCEPT WHERE LINED THROUGH. /JEA/ DE 7096175 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04, ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Substitute for form 1449B/PTO

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

MAR 0 7 2003 ECH CENTAR 1600/2900 Complete if Known **Application Number** 09/432,503 Filing Date November 2, 1999 **First Named Inventor** Cech, Thomas R., et. ald 1652 Art Unit **Examiner Name** Peter P. Tung

(use as many sheets as necessary)

015389-002611US Sheet Attorney Docket Number

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	во	1994 Genome Issue of <i>Science</i> (265:1981f)	
	ВР	Anderson and Young, "Quantitative Filter Hybridization" in Nucleic Acid Hybridization pp73-111 (1985)	
	BQ	Ausubel et al.; (1989); Current Protocols in Molecular Biology; pp 5.1-5.11, 16.1-16.3 and 16.9-16.20; John Wiley & Sons, New York NY	
	BR	Autexier et al., "Reconstitution of human telomerase activity and identification of a minimal functional region of the human telomerase RNA," (1996) EMBO J, 15:5928	
	BS	Auxexier and Greider, "Functional reconstitution of wild-type and mutant <i>Tetrahymena</i> telomerase," (1994) <i>Genes Develop.</i> , 8:563	
	вт	Berger and Kimmel, Guide to Molecular Cloning Techniques; (1987); Meth. Enzymol.; vol. 152; pp 305-389; Academic Press; San Diego CA	
	BU	Biessman et al., "Addition of Telomere-Associated HeT DNA Sequences "Heals" Broken Chromosome End s in Drosophila," (1990) Cell, 61:663	
	BV	Bitter et al., "Expression and secretion vectors for yeast," Meth Enzymol., (1987) 153:516	
	BW	Blackburn and Chiou, "Non-nucleosomal packaging of a tandemly repeated DNA sequence at termini of extrachromosomal DNA coding for rRNA in Tetrahymena," (1981) <i>Proc. Natl. Acad. Sci.</i> , 78:2263	
	вх	Blackburn and Gall, " A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in <i>Tetrahymena</i> , " (1978) <i>J. Mol. Biol.</i> , 120:33	
	BY _	_Blackburn,-"Telomerases,"-(1992) <i>AnnRev. Biochem.</i> , 61:113	
		Bodnar et al., "Extension of Life-Span by Introduction of Telomerase into Normal Human Cells," (1998) Science, 279:349	
		Bradford, "A Rapid and Sensitive method for the Quantitation of Microgram Quantities of Protein Utilizing the Principle of Protein-Dye Binding," (1976) <i>Anal. Biochem.</i> , 72:248	
-		Braunstein et al., "Transcriptional silencing in yeast is associated with reduced nucleosome acetylation," (1993) Genes Develop., 7:592	

Examiner	Date	
Signature		
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant,

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Receipt chare: 03/0488003

Substitute for form 1449B/PTO

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Begin Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB contains and including the contains an

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number

09/432,503

Filing Date

November 2, 1999

First Named Inventor

Art Unit

1652

Examiner Name

Complete if Known

09/432,503

November 2, 1999

MAR 0

Cech, Thomas R., et

(use as many sheets as necessary)

Sheet 6 of 12

Attorney Docket Number 015389-002611US

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Calvio et al., "Identification of hnRNP P2 as TLS/FUS using electrospray mass spectrometry," (1995) RNA, 1:724	
		Caruthers et al., "New chemical methods for synthesizing polynucleotides," (1980) Nucleic Acids Res. Symp. Ser., 215-223	
		Chan and Tye, "Organization of DNA sequences and replication origins at yeat telomeres, " (1983) Cell, 33:563	
		Colbere-Garapin et al., "A new dominat hybrid selective marker for higher eukaryotic cells," (1981) J. Mol. Biol., 150:1	
		Cole et al., "The EBV-hybridoma technique and its application to human lung cancer," Monoclonal Antibodies and Cancer Therapy, Alan R. Liss Inc., New York NY 77-96 (1985)	
		Collins et al., "Purification of Tetrahymena telomerase and cloning of genes encoding the two peotein components of the enzyme," (1995) Cell, 81:677	
		Conrad et al., "RAP1 protein interacts with yeast telomers in vivo: Overproduction alters telomere structure and decreases chromosome stability," (1990) Cell, 63:739	
		Coombs, Dictionary of Biotechnology. (1994); pp. 101-102, 283, 301 and 332; Stockton Press, New York NY	
		Cote et al., "Generation of human monoclonal antibodies reactive with cellular antigens," (1983) Proc. Natl. Acad. Sci., 80:2026	
		Counter et al., "The catalytic subunit of yeast telomerase," (1997) Proc. Natl. Acad. Sci., 94:9202	
		Counter et al., (1994) Proc. Natl. Acad. Sci., 91:2900	
,		Creighton; Proteins, Structures and Molecular Principles; (1983); pp. 1-60; WH Freeman and Co; New York, NY	
		Dieffenbach and Dveksler; PCR Primer, a Laboratory Manual; (1995) pp. 131-156, 453-462 and 507-580; Cold Spring Harbor Press, Plainview NY	
		Duplaa et al., "Quantitative analysis of polymerase chain reaction products using biotinylated dUTP incorporation," (1993) Anal. Biochem., 212:229	

				
Examiner	i	Date		
Signature		Considered		

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DE 7096175 v1

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Receipt date 03/04/2003

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Pasework Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 449B/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/432,503

Filing Date November 2, 1999

First Named Inventor Cech, Thomas R., et. al.

Art Unit 1652

Examiner Name Peter P. Tung

(use as many sheets as necessary)

 Sheet
 7
 of
 12
 Attorney Docket Number
 015389-002611US

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Τ²
		Fang et al., "Oxytricha telomere-binding protein: separable DNA-binding and dimerization domains of the α -subunit," Genes Develop. 7:870 (1993) and Gray et al., (1991) Cell 67:807	
		Feng et al., "The RNA Componant of Human Telomerase," (1995) Science, 269:1236	
		GenBank Accession No. AA281296; April 2, 1997	
		Genbank accession no. AA299878: April 18, 1997	
		Genbank accession no. AA311750; April 19, 1997	
		Gilley et al., "Altering specific telomerase RNA template residues affects active site function," (1995) Genes Develop., 9:2214	
		Gottschling and Cech, "Chromatin Structure of the Molecular Ends of Oxytricha Mononuclear DNA: Phased Nucleosomes and a Telomeric Complex," (1984) Cell, 38:501	
		Gottschling and Zakian, "Telomere proteins: specific recognition and protection of the natural termini of Oxytricha macronuclear DNA," (1986) Cell 47:195	
		Grant et al., Meth Enzymol., (1987) 153:516-544	
		Greenwood et al., "Phylogenetic relationships within the class oligohymenophorea, phylum ciliophora, inferred from the complete small subunit rRNA gene sequences of Colpidium campylum, Glaucoma chattoni, and Opisthonecta henneguyi," (1991) J. Mol. Evol., 3:163	
		Greider and Blackburn, "A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat _synthesis," (1989). Nature, .337:331	
		Greider and Blackburn, "Identification of a specific telomere terminal transferase activity in Tetrahymena extracts," (1985) Cell, 43:405	
		Greider, "Telomerase is processive, " (1991) Mol. Cell. Biol., 11:4572	
		Greider, "Telomere Length Regulation," (1996) Ann. Rev. Biochem., 65:337	

Examiner	Date	
Signature	 Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Receipt date: 03/04/2003

Substitute for form 1449B/PTO

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless it contains a valid OMB contains and the collection of information unless are collected unless and the collection of information unless are collected unless and the collection of information unless are collected unless and the collection of information unless are collected unless and the collection of information unless are collected unless and the collection unless are collected unless and the collection unless are collected unless and the collection unless are collected unle

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/432,503 MAP 7

Filing Date November 2, 1999 7

First Named Inventor Cech, Thomas R., et. siCH CENTER 1600/2900

Art Unit 1652

Examiner Name Peter P. Tung

(use as many sheets as necessary)

Sheet 8 of 12 Attorney Docket Number 015389-002611US

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т
		Hampton et al.; Serological Methods a Laboratory Manual; (1990); pp. 33-86, 179-286; APS Press, St Paul MN	
		Harrington et al., "A Mammalian Telomerase-Associated Protein," (1997) Science, 275:973	
		Harrington et al., "Human telomerase contains evolutionarily conserved catalytic and structural subunits," (1997) Genes Dev., 11:3109	
		Hartman and Mulligan, "Two dominant-acting selectable markers for gene transfer studies in mammalian cells," (1988) Proc. Natl. Acad. Sci., 85:8047	
		Henderson and Blackburn, "An overhanging 3' terminus is a conserved feature of telomeres," (1989) <i>Mol Cell. Biol.</i> , 9:345	
		Horn et al., "Synthesis of oligonucleotides on cellulose. Part II: design and synthetic strategy to the synthesis of 22 oligodeoxynucleotides coding for gastric inhibitory polypeptide (GIP)," (1980) Nucleic Acids Res. Symp. Ser., 225-232	
		Hudson et al., "An STS-based map of the human genome," (1995) Science, 270:1945	
		Huse et al., "Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda," (1989) Science, 246:1275	
		Johnson et al., (1991) Mol. Cell Biol. 11:1	
		Kilian et al., "Isolation of a candidate human telomerase catalytic subunit gene, which reveals complex splicing patterns in different cell types," (1997) Hum. Mol. Genet., 6:2011	
		Kipling and Cooke, "Hypervariable ultra-long telomeres in mice," (1990) Nature 347:400	
<i>**</i>		Klobutcher et al., "All gene-sized DNA molecules in four species of hypotrichs have the same terminal sequence and an unusual 3' terminus," (1981) Proc. Natl. Acad. Sci., 78:3015	
		Koehler and Milstein, "Continuous cultures of fused cells secreting antibody of predefined specificity," (1975) Nature 256:495	
		Kosbor et al., "The production of monoclonal antibodies from human lymphocytes," (1983) Immunol. Today 4:72	

Examiner Da	Date
	Considered

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Sheet

PTO/SB/08B (10-01) Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

015389-002611US

Substitute for form 1449B/PTO Complete if Known **Application Number** 09/432,503 INFORMATION DISCLOSURE Filing Date November 2, 1999 STATEMENT BY APPLICANT **First Named Inventor** Cech, Thomas R., et. al. Art Unit 1652 (use as many sheets as necessary) **Examiner Name** Peter P. Tung

Attorney Docket Number

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Т:
		Lamond and Sproat; (1994)"Isolation and Characterization of Ribonucleoprotein Complexes;" In RNA Processing: A Practical Approach; (Higgins, S.J. and Hawes, B.D, Eds.), Volume 1; pp103-140	
		Lamond et al., "Probing the structure and function of U2 snRNP with antisense oligonucleotides made of 2'-OMe RNA," (1989) Cell, 58:383	
		Lendvay et al., "Senescence mutants of Saccharomyces cerevisiae with a defect in telomere replication identify three additional EST genes," (1996) Genetics, 144	
		Lingler et al., "Purification of telomerase from Euplotes adeiculatus: requirement of a primer 3' overhang," (1996) Proc. Natl. Acad. Sci., 93:10712	
		Lingler et al., "Reverse transcriptase motifs in the catalytic subunit of telomerase," (1997) Science, 276:561	
		Lingner et al., " Telomerase RNAs of different ciliates have a common secondary structure and a permuted template, " (1994) Genes Develop., 8:1984	
		Lingner et al., "Telomerase and DNA End Replication: No Longer a Lagging Strand Problem?," (1995) Science 269:1533	
		Lowy et al., "Isolation of transforming DNA: Cloning the hamster aprt gene," (1980) Cell, 22:817	
		Lustig and Petes, Identification of yeast mutants with altered telomere structure," (1986) Proc. Natl. Acad. Sci., 83:1398	
		Maddox et al., "Elevated serum levels in human pregnancy of a molecule immunochemically similar to eosinophil granule major basic protein," (1983) J. Exp. Med., 158:1211	
		Makarov et al., "Nucleosomal Organization of Telomere-Specific Chromatin in Rat," (1993) Cell, 73:775	
		McEachern and Blackburn, "runaway telomere elongation caused by telomerase RNA gene mutation," (1995) Nature, 376:403	
		Melby et al., "Quantitative measurement of human cytokine gene expression by polymerase chain reaction," (1993) J. Immunol. Meth., 159:235	
		Merrifield, "Solid phase peptide synthesis. I. The synthesis of a tetrapeptide," (1963) J. Am. Chem. Soc., 85:2149	

Examiner	·	Date	
Signature		Considered	·

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

PTO/SP/08P / 10 01 \

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Paperwork Registron Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Complete if Known

Application Number 09/432,503

Filing Date November 2, 1999

First Named Inventor Cech, Thomas R., et. al.

Art Unit 1652

Examiner Name Peter P. Tung

(use as many sheets as necessary)

Substitute for form 1449B

Sheet 10 of 12 Attorney Docket Number 015389-002611US

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²
		Meyerson et al., "hEST2, the Putative Human Telomerase Catalytic Subunit Gene, Is Up-Regulated in Tumor Cells and during Immortalization," (1997) Cell, 90:785	
		Murray, In McGraw Hill Yearbook of Science and Technology, (1992) McGraw Hill, New York NY, pp 191-196	
		Nakamura et al., "Telomerase Catalytic Subunit Homologs from Fission Yeast and Human," (1997) Science, 277:955	
		Nakayama et al., "TLP1: A Gene Encoding a Protein Component of Mammalian Telomerase Is a Novel Member of WD Repeats Family," (1997) Cell,88:875	
		Nielsen et al., (1993) "Peptide nucleic acids (PNAs): Potential antisense and anti-gene agents," Anticancer Drug Des., 8:53	
		Oka et al., "Inverted terminal repeat sequence in the macronuclear DNA of Stylonychia pustulata, " (1980) Gene, 10:301	
		Olovnikov, "A theory of marginotomy: The incomplete copying of template margin in enzymic synthesis of polynucleotides and biological significance of the phenomenon," (1973) <i>J. Theor. Biol.</i> , 41:181	
		Orlandi et al., "Cloning immunoglobulin variable domains for expression by the polymerase chain reaction," (1989) Proc. Natl. Acad. Sci., 86:3833	
		Prescott, "The DNA of ciliated protozoa," (1994) Microbiol. Rev., 58:233	
-		Price, (1993) Blood Rev., 7:127	
		Rhodes et al., "Transformation of maize by electroporation of embryos," (1995) Meth. Mol. Biol., 55:121	
		Roberge et al., "A strategy for a convergent synthesis of N-linked glycopeptides on a solid support," (1995) Science, 269:202	
		Romero and Blackburn, "A conserved secondary structure for telomerase RNA, " (1991) Cell, 67:343	
		Sambrook et al.; Molecular Cloning, A Laboratory Manual; (1989); pp. 8.1-8.86 and 16.1-17.44; Cold Spring Harbor Press, Plainview NY	

Examiner	Date	
Signature	Considered	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Receipt date: 03/64/20

Sheet

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

he Paperwork Rection Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449B/PAPE

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

of

Complete if Known **Application Number** 09/432,503 Filing Date November 2, 1999 **First Named Inventor** Cech, Thomas R., et. al. Art Unit 1652 **Examiner Name** Peter P. Tung 015389-002611US Attorney Docket Number

(use as many sheets as necessary) 12

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the T ² Cite Examiner item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue No.1 Initials * number(s), publisher, city and/or country where published. Sandell et al., "Transcription of yeast telomere alleviates telomere position effect without affecting chromosome stability, "(1994) Proc. Natl. Acad. Sci., 91:12061 Sanger et al., "DNA sequencing with chain-terminating inhibitors," (1977) Proc. Natl. Acad. Sci., 74:5463 Scharf et al., "Heat stress promoters and transcription factors," (1994) Result Probl. Cell Differ. 20:125 Shampay and Blackburn, "Generation of telomere-length heterogeneity in Saccharomyces cerevisiae," (1988) Proc. Natl. Acad. Sci., 85:534 Sheen and Levis, "Transposition of the LINE-like retrotransposon TART to Drosophila chromosome termini," (1994) Proc. Natl. Acad. Sci., 91:12510 Singer and Gottschling, "TLC1: Template RNA Component of Saccharomyces cerevisiae Telomerase," (1994) Science 266:404 Starling et al., "Extensive telomere repeat arrays in mouse are hypervariable," (1990) Nucleic Acids Res., 18:6881 Swanton et al., "Arrangement of Coding and Non-coding Sequences in the DNA Molecules Coding for rRNAs in Oxytricha sp.," (1980) Chromosoma 77:203 Tommerup et al., "Unusual chromatin in human telomeres," (1994) Mol. Cell. Biol., 14:5777 Trask, "Fluorescence in situ hybridization: application in cytogenetics and gene mapping," (1991) Trends Genet., 7:149 Verma et al.; "Human Chromosomes: A Manual of Basic Techniques;" (1988); pp. 4-30, 152-190; Pergamon Press, Watson, "Origin of concatermeric T7 DNA," (1972) Nature New Biol., 239:197 Weinrich et al., "Reconstitution of human telomerase with the template RNA component hTR and the catalytic protein subunit hTRT," (1997) Nat. Genet., 17(4):498-502 Wellinger et al., "Origin activation and formation of single-strand TG1.3 tails occur sequentially in late S phase on a

	Examiner Signature		Date Considered	
--	-----------------------	--	--------------------	--

Yeast linear plasmid," (1993) Mol. Cell. Biol., 13:4057

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Receipt date: 03/04/

PTO/SB/08B (10-01)
Approved for use through 10/31/2002. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

the Paperwork Resolution Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number Substitute for form 1449B/FTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Application Number 09/432,503 **Filing Date** November 2, 1999 **First Named Inventor** Cech, Thomas R., et. al. Art Unit 1652 **Examiner Name** Peter P. Tung

Complete if Known

(use as many sheets as necessary)

Sheet of 12 015389-002611US Attorney Docket Number

		OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS	
Examiner Initials *	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
		Wellinger et al., "Saccharomyces Telomeres Acquire Single-Strand TG _{1.3} Tails Late in S Phase," (1993) Cell 72:51	
		Whitehead Institute/MIT Center for Genome Research, Genetic Map of the Mouse, Database Release 10, APril 28, 1995	
		Wigler et al., "Transfer of purified herpes virus thymidine kinase gene to cultured mouse cells," (1977) Cell, 11:223	
		Wigler et al., "Transformation of mammalian cells with an amplifiable dominant-acting gene," (1980) Proc. Natl. Acad. Sci., 77:3567	
		Winter and Milstein, "Man-made antibodies," (1991) Nature, 349:293	
		Wright et al., "Saccharomyces telomeres assume a non-nucleosomal chromatin structure, " (1992) Genes Develop., 6:197	
		Yu et al., "In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs," (1990) Nature, 344:126	
		Zahler and Prescott, "Telomere terminal transferase activity in the hypotrichous ciliate Oxytricha nova and a model for replication of the ends of linear DNA molecules," (1988) Nucleic Acids Res., 16:6953	
		Zakian, Telomeres: Beginning to Understand the End," (1995) Science 270:1601	
		Zaug et al., "Catalysis of RNA Cleavage by a Ribozyme Derived from the Group I Intron of Anabaena Pre-tRNA ^{Leu} ;" (1996); Nucleic Acids Research; 24:532-533	

Examiner Signature	/Jon Eric Angell/	Date Considered	03/26/2009	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

03/04/2003 09432503 - GAU: 1635 U.S. Patent and Trademark Onice: U.S. DEPARTMENT OF COMMERCE Wholen Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. TECH CENTER 1600/2900 09/432,503 Application Number TRANSMITTAL Filing Date November 2, 1999 **FORM** First Named Inventor Cech, Thomas R. (to be used for all correspondence after initial filing) Art Unit 1652 **Examiner Name** Delia M. Ramirez Total Number of Pages in This Submission Attorney Docket Number 015389-002611US ENCLOSURES (Check all that apply) Drawing(s) (103 pages formal After Allowance Communication to Fee Transmittal Form drawings) Appeal Communication to Board of __ Fee Attached Licensing-related Papers Appeals and Interferences Petition Appeal Communication to Group Amendment / Reply (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information Provisional Application Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Terminal Disclaimer Other Enclosure(s) Extension of Time Request (please identify below): Request for Refund Return Postcard; Amendment -Express Abandonment Request Submission of Substitute Specification; □ CD, Number of CD(s) Substitute Specification; Marked-up Information Disclosure Statement version of specification; original Appointment of Associate Attorney copies of 3 of the cited (submitted by facsimle on 12/2/02) references) The Commissioner is authorized to charge any additional fees to Certified Copy of Priority Deposit Account 20-1430. Remarks Document(s) Response to Missing Parts/ Incomplete Application Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT Townsend and Townsend and Crew LLP Firm Scott L. Ausenhus Reg. No. 42,271 Individual Signature

Date February 25, 2003 CERTIFICATE OF TRANSMISSION/MAILING I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date: February 25, 2003 Typed or printed Maisie C. Livengood Maisir C. Leveryood

Signature

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231. If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2. DE 7096225 v1

Date

February 25, 2003

Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. ce: U.S. DEPARTMENT OF COMMERCE

GEE TO ANO	54177 A I		Complete if Known	RECENT
∕ 🥞 FEE TRANS	MIIIAL	Application Number	09/432,503	PIVED
FEE TRANS for FY 2	003	Filing Date	November 2, 1999	MAR 0 7 2003
Patent fees are subject to a	nnual revision.	First Named Inventor	Cech, Thomas R.	tCH Crain
Applicant claims small entity sta	tus. See 37 CFR 1.27	Examiner Name	Delia M. Ramirez	CENTER 1600/200
		Group Art Unit	1652	000/290
TOTAL AMOUNT OF PAYMENT	(\$) 180	Attorney Docket No.	015389-002611US	

METHOD OF PAYMENT (check all that apply)					FEE C	ALCULATION (continued)	
Check Credit Card MoneyOrder Other	one	3. ADDITIONAL FEES					
Deposit Account:		Large	Entity	Small	Entity		
Deposit		Fee Code	Fee (\$)	Fee Code	Fee (\$)	Fee Description	Fee Paid
Account 20-1430		1051	130	2051	65	Surcharge - late filing fee or oath	
		1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
Deposit Account Townsend and Townsend and Crew LLP	1	1053	130	1053	130	Non-English specification	
Name		1812	2,520	1812	2,520	For filing a request for reexamination	
The Commissioner is authorized to: (check all that apply)		1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
Charge fee(s) indicated below Credit any overpayments Charge any additional fee(s) during the pendency of this application		1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
Charge fee(s) indicated below, except for the filing fee		1251	110	2251	55	Extension for reply within first month	
to the above-identified deposit account.		1252	410	2252	205	Extension for reply within second	
FEE CALCULATION				1		month	
1. BASIC FILING FEE		1253	930	2253	465	Extension for reply within third month	
Large Entity Small Entity		1254	1,450	2254	725	Extension for reply within fourth month	
Fee Fee Fee Fee Description	.tu	1255	1,970	2255	985	Extension for reply within fifth month	
Code (\$) Code (\$) Fee P 1001 750 2001 375 Utility filing fee	110	1401	320	2401	160	Notice of Appeal	
1001 750 2001 375 Utility filing fee 1002 330 2002 165 Design filing fee		1402	320	2402	160	Filing a brief in support of an appeal	
		1403	280	2403	140	Request for oral hearing	
1003 520 2003 260 Plant filing fee 1004 750 2004 375 Reissue filing fee		1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1005 160 2005 80 Provisional filing fee		1452	110	2452	55	Petition to revive – unavoidable	
CUDTOTAL (4)		1453	1,300	2453	650	Petition to revive – unintentional	
SUBTOTAL (1)	SUBTOTAL (1) (\$)			2501	650	Utility issue fee (or reissue)	
. EXTRA CLAIM FEES FOR UTILITY AND REISSUE			470	2502	235	Design issue fee	
			630	2503	315	Plant issue fee	
Fees from Extra Claims below Fee	Paid	1460	130	1460	130	Petitions to the Commissioner	
Total Claims -** = = =		1807	50	1807	50	Petitions related to provisional applications	
Independent Claims = = =		1806	180	1806	180	Submission of Information Disclosure Stmt	180
Multiple Dependent		8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
Large Entity Small Entity Fee Fee Fee Fee Fee Fee Fee Fee Fee Fe		1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
Code (\$) Code (\$) Fee Description		1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1202 18 2202 9 Claims in excess of 20 1201 84 2201 42 Independent claims in exces	s of 3	l		l		Request for Continued Examination	
1203 280 2203 140 Multiple dependent claim, if		1801	750	2801	375	(RCE)	
1204 84 2204 42 ** Reissue independent clair over original patent	•	1802	900	1802	900	Request for expedited examination of a design application	
1205 18 2205 9 Reissue claims in excess and over original patent	of 20	Other fe	e (specify	/)			
SUBTOTAL (2) (\$)		*Reduce	ed by Bas	ic Filing	Fee Pai	d SUBTOTAL (3) (\$)180	
**or number previously paid, if greater; For Reissues, see above		<u></u>					

SUBMITTED BY				Cc	omplete (if applicable)	
Name (Print/Type)	Scott L. Ausennus	Registration No. (Attorney/Agent)	42,271	Telephone	303-571-4000	
Signature	_ sot \	merant		Date	February 25, 2003	

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.